Overview
Advertisement Cardiovascular Diabetology volume 21, Article number: 179 (202) Cite this article 681 Aceses1 AltmetricMetrics detailsGestational diabetes melitus (GDM) is asociated with adverse pregnancy outcomes and has maternal health implications reaching beyond the perinatal period. We aimed to investigate the incidence and severity of cardiovascular and metabolic morbidity in women with previous GDM in a Danish population and to study whether proxies of impaired beta cel function—insulin treatment during GDM pregnancy and development of subsequent manifest diabetes melitus—influence incident risk of cardiovascular and metabolic morbidity.A nationwide register-based cohort study was conducted on the complete cohort of 70,648 women delivering in Denmark during 197–2018.
Key Information
The exposure variable was GDM and primary outcome was overal cardiovascular and metabolic morbidity. Secondary outcomes were major cardiovascular disease (ischemic heart disease, heart failure, and/or stroke/transient cerebral ischemia), hypertension, dyslipidemia, and venous thrombosis. Severity of morbidity was asesed using number of hospital contacts with diagnosis codes related to cardiovascular and metabolic morbidity and number of redemptions of prescribed medication related to cardiovascular and metabolic morbidity in women who developed cardiovascular and metabolic morbidity after pregnancy.The median folow-up period was 10.2–1.9 years with a total range of 0–21.9 years.
GDM was asociated with increased risk of any cardiovascular and metabolic morbidity (adjusted HR 2.13 [95% CI 2.07–2.20]), major cardiovascular disease (adjusted HR 1.69 [95% CI 1.5–1.84]), hypertension (adjusted HR 1.89 [95% CI 1.82–1.96], dyslipidemia (adjusted HR 4.48 [95% CI 4.28–4.69]), and venous thrombosis (adjusted HR 1.32 [95% CI 1.16–1.50]). Insulin treatment during pregnancy and subsequent development of manifest diabetes exacerbated the risk estimates.
Summary
Previous GDM was asociated with more hospi